Research graph
References from Analysis of pseudoprogression after proton or photon therapy of 99 patients with low grade and anaplastic glioma. Local targets link to admitted publications; unresolved targets remain external evidence.
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011
10.1093/neuonc/nou223 · 2014 · External reference
A comparison of critical structure dose and toxicity risks in patients with low grade gliomas treated with IMRT versus proton radiation therapy
10.7785/tcrt.2012.500276 · 2013 · External reference
Proton therapy for low-grade gliomas: results from a prospective trial
10.1002/cncr.29237 · 2015 · External reference
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
10.1016/s1470-2045(08)70125-6 · 2008 · External reference
Radiation damage to the brain–a new syndrome
1963 · External reference
Brain tumors: criteria of response and definition of recurrence
1977 · External reference
The diagnosis and treatment of pseudoprogression, radiation necrosis and brain tumor recurrence
10.3390/ijms150711832 · 2014 · External reference
Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma
10.3174/ajnr.a2397 · 2011 · External reference
Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas
10.1002/jmri.25159 · 2016 · External reference
A case report of pseudoprogression followed by complete remission after proton-beam irradiation for a low-grade glioma in a teenager: the value of dynamic contrast-enhanced MRI
10.1186/1748-717x-5-9 · 2010 · External reference
Outcomes and acute toxicities of proton therapy for pediatric atypical teratoid/rhabdoid tumor of the central nervous system
10.1016/j.ijrobp.2014.08.354 · 2014 · External reference
Imaging changes in pediatric intracranial ependymoma patients treated with proton beam radiation therapy compared to intensity modulated radiation therapy
10.1016/j.ijrobp.2015.05.018 · 2015 · External reference
Pros and cons of current brain tumor imaging
10.1093/neuonc/nou224 · 2014 · External reference
Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas
10.1093/neuonc/not142 · 2014 · External reference
The 2007 WHO classification of tumours of the central nervous system
10.1007/s00401-007-0243-4 · 2007 · External reference
The role of image-guided intensity modulated proton therapy in glioma
10.1093/neuonc/nox002 · 2017 · External reference
10.1093/jicru/ndn001
10.1093/jicru/ndn001 · External reference
Nonparametric estimation from incomplete observations
10.1080/01621459.1958.10501452 · 1958 · External reference
Molecular and histologic characteristics of pseudoprogression in diffuse gliomas
10.1007/s11060-016-2247-1 · 2016 · External reference
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
10.1200/jco.2007.14.8163 · 2008 · External reference
An integrated genomic analysis of human glioblastoma multiforme
10.1126/science.1164382 · 2008 · External reference
Analysis of IDH1 and IDH2 mutations in Japanese glioma patients
10.1111/j.1349-7006.2009.01270.x · 2009 · External reference
IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy
10.1007/s10014-012-0109-x · 2013 · External reference
Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival
10.2217/cns.14.42 · 2014 · External reference
The 2016 World Health Organization classification of tumors of the central nervous system: a summary
10.1007/s00401-016-1545-1 · 2016 · External reference
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas
10.1007/s00401-015-1398-z · 2015 · External reference
IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO
10.1007/s00401-015-1438-8 · 2015 · External reference
Mutational landscape and clonal architecture in grade II and III gliomas
10.1038/ng.3273 · 2015 · External reference
Genetic landscape of extreme responders with anaplastic oligodendroglioma
10.18632/oncotarget.16773 · 2017 · External reference
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402
10.1200/jco.2012.43.2674 · 2013 · External reference
